326 related articles for article (PubMed ID: 10674778)
1. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection.
Robinson RF; Nahata MC
Am J Health Syst Pharm; 2000 Feb; 57(3):259-64. PubMed ID: 10674778
[TBL] [Abstract][Full Text] [Related]
2. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
[TBL] [Abstract][Full Text] [Related]
3. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
Meissner HC; Long SS;
Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
[TBL] [Abstract][Full Text] [Related]
4. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
5. Palivizumab for respiratory syncytial virus prophylaxis.
Sandritter T
J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
[TBL] [Abstract][Full Text] [Related]
6. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.
Wu H; Pfarr DS; Losonsky GA; Kiener PA
Curr Top Microbiol Immunol; 2008; 317():103-23. PubMed ID: 17990791
[TBL] [Abstract][Full Text] [Related]
7. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.
Groothuis JR; Simoes EA; Hemming VG
Pediatrics; 1995 Apr; 95(4):463-7. PubMed ID: 7700741
[TBL] [Abstract][Full Text] [Related]
8. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
Resch B; Müller W
Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
[TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus immune globulin: decisions and costs.
Barton LL; Grant KL; Lemen RJ
Pediatr Pulmonol; 2001 Jul; 32(1):20-8. PubMed ID: 11416872
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus (RSV) as a common cause of respiratory illness in children younger than 5 years.
Poehling KA; Hickson GB
Ambul Pediatr; 2003; 3(6):342-4. PubMed ID: 14616052
[No Abstract] [Full Text] [Related]
11. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection.
Morris SK; Dzolganovski B; Beyene J; Sung L
BMC Infect Dis; 2009 Jul; 9():106. PubMed ID: 19575815
[TBL] [Abstract][Full Text] [Related]
12. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).
Groothuis JR; Nishida H
Pediatr Int; 2002 Jun; 44(3):235-41. PubMed ID: 11982888
[TBL] [Abstract][Full Text] [Related]
13. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater
Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438
[TBL] [Abstract][Full Text] [Related]
15. Strategies for preventing respiratory syncytial virus.
Forbes M
Am J Health Syst Pharm; 2008 Dec; 65(23 Suppl 8):S13-9. PubMed ID: 19020197
[TBL] [Abstract][Full Text] [Related]
16. Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody.
Huang K; Wu H
Microbiol Spectr; 2014 Aug; 2(4):AID-0014-2014. PubMed ID: 26104207
[TBL] [Abstract][Full Text] [Related]
17. Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. (American Academy of Pediatrics).
Canfield SD; Simoes EA
Pediatr Ann; 1999 Aug; 28(8):507-14. PubMed ID: 10483596
[No Abstract] [Full Text] [Related]
18. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
19. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways.
Piedimonte G; King KA; Holmgren NL; Bertrand PJ; Rodriguez MM; Hirsch RL
Pediatr Res; 2000 Mar; 47(3):351-6. PubMed ID: 10709734
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.
Sáez-Llorens X; Castaño E; Null D; Steichen J; Sánchez PJ; Ramilo O; Top FH; Connor E
Pediatr Infect Dis J; 1998 Sep; 17(9):787-91. PubMed ID: 9779762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
